Corbus Pharmaceuticals Announces Phase 2b Study of Lenabasum for Treatment of Cystic Fibrosis Did Not Meet Primary Endpoint
06. Oktober 2020 07:05 ET
|
Corbus Pharmaceuticals Holdings, Inc.
Study did not meet primary endpoint of reducing rate of pulmonary exacerbationsLenabasum treatment had a favorable safety profile and was well-toleratedData to be presented at the upcoming North...